Merz's Acquisition of Acorda's Assets and Securing Inbrija's Regulatory Status

German pharmaceutical company Merz Therapeutics has acquired the rights to Inbrija (active ingredient: levodopa inhalation powder), a Parkinson's disease treatment, through Acorda Therapeutics' bankruptcy proceedings. The update to the FDA's NDA 209184 regulatory database indicates that the ownership and commercialization rights have been officially transferred to Merz as part of this acquisition. By incorporating Acorda's key asset, which was facing financial difficulties, into the financially stable Merz, patients can continue to receive uninterrupted access to the medication. The regulatory agency's data update is not merely an administrative procedure but also a declaration that the quality assurance and efficacy monitoring of the treatment will be maintained stably under the new owner.

Differentiated Inhalation Advantage in the Parkinson's Disease OFF Episode Market

Inbrija is the first inhaled levodopa formulation for treating OFF episodes (periods of diminished medication effectiveness) in Parkinson's disease patients who are already taking carbidopa/levodopa oral medications. OFF episodes are characterized by a sudden decline in motor function, and conventional oral medications have difficulty providing rapid relief due to delayed gastrointestinal absorption. In contrast, Inbrija utilizes the ARSUS inhalation technology to deliver the drug directly to the lungs, rapidly increasing dopamine levels in the bloodstream and helping patients return to their daily activities. It serves as a rescue therapy. Compared to invasive injectable medications or sublingual films, it offers a more convenient route of administration, significantly improving patient compliance and quality of life.

Portfolio Diversification and Financial Synergy Through Bankruptcy Proceedings

In July 2024, Merz acquired Inbrija and Ampyra, a multiple sclerosis treatment, from Acorda for $185 million in cash as part of a Section 363 asset sale in the U.S. bankruptcy court. Acorda had previously overcome CMC issues and invested in Phase 3 clinical trials but ultimately filed for bankruptcy. However, the products themselves have proven commercial value. Through this acquisition, Merz has successfully secured late-stage assets that generate immediate revenue while minimizing R&D risk. This, combined with Merz's existing neurology business infrastructure, is expected to create financial synergies by increasing its market share in the North American specialty pharmaceutical market.

Prospects for Future Commercial Growth and Global Market Expansion

The global Parkinson's disease market is estimated at $6 billion to $8 billion as of 2025, and the unmet need is increasing due to the aging population. In the market, Inbrija competes with other drugs such as Apokyn (subcutaneous injection) and Kynmobi (sublingual film) for the leading position in OFF episode treatment. Merz is expected to strengthen its marketing and distribution channels and accelerate revenue growth following the completion of this regulatory transfer. Whether Merz will accelerate its expansion into global territories, including Europe (EMA) and Asia, with its stable capital will be a key variable in its long-term value growth.